Hafrun Fridriksdottir - Teva Pharmaceutical President
| TEVA Stock | ILA 7,798 171.00 2.15% |
President
Dr. Hafrun Fridriksdottir serves as Executive Vice President Global RD of Teva Pharmaceutical Industries Limited. Dr. Fridriksdottir became Executive Vice President, Global RD in November 2017. From February 2017 to November 2017, she served as Executive Vice President, President of Global Generics RD, after serving as Senior Vice President and President of Global Generics RD from 2016. Prior to joining Teva, from 2015 to 2016, Dr. Fridriksdottir served as Senior Vice President and President of Global Generics RD in Allergan plc. From 2002 to 2015, she held positions of increasing responsibility within the Actavis Group, including Senior Vice President, RD. From 1997 to 2002, Dr. Fridriksdottir served as Divisional Manager of Development at Omega Pharma, until its merger with Actavis since 2017.
| Age | 57 |
| Tenure | 8 years |
| Phone | (972) 3 914 8213 |
| Web | www.tevapharm.com |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Avi Strum | Tower Semiconductor | 61 | |
| Zeev Gofer | Elbit Systems | 66 | |
| Ilan Pacholder | Elbit Systems | 64 | |
| Itzhak Edrei | Tower Semiconductor | 58 | |
| Ilan Rabinovich | Tower Semiconductor | 61 | |
| Shelly Gordon | Elbit Systems | 58 | |
| Yehoshua Yehuda | Elbit Systems | 55 | |
| Nati Somekh | Tower Semiconductor | 48 | |
| Edgar Maimon | Elbit Systems | 64 | |
| Marco Racanelli | Tower Semiconductor | 56 | |
| Yehudit Grisaro | El Al Israel | 61 | |
| Elad Aharonson | Elbit Systems | 45 | |
| Yoram Shmuely | Elbit Systems | 62 | |
| Yehuda Vered | Elbit Systems | 65 | |
| Yuval Ramon | Elbit Systems | 57 | |
| Jonathan Ariel | Elbit Systems | 62 | |
| Yossi Netzer | Tower Semiconductor | 59 | |
| David Temin | Elbit Systems | 67 | |
| Gary Saunders | Tower Semiconductor | 54 | |
| Ran Kril | Elbit Systems | 52 | |
| Avi Mizrachi | Elbit Systems | 60 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nechemia Peres, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Janet Vergis, Independent Director | ||
| Amir Weiss, VP Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Ex Portfolio | ||
| Abbas Hussain, Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
| Kathleen Veit, Global VP | ||
| Deborah Griffin, Chief Accounting Officer | ||
| Perry Nisen, Independent Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Kevin Mannix, Vice President Head of Investor Relations | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Andrew Weil, Chief Accounting Officer | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 102.13 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 2.32 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.